Advertisement

Topics

Latest "Biogen Incorporated" News Stories

09:31 EDT 15th August 2018 | BioPortfolio

Here are the most relevant search results for "Biogen Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Biogen Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biogen Incorporated for you to read. Along with our medical data and news we also list Biogen Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biogen Incorporated Companies for you to search.

Showing "Biogen Incorporated" News Articles 1–25 of 652

Wednesday 15th August 2018

Sunesis Pharmaceuticals Inc SNSS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummarySunesis Pharmaceuticals Inc Sunesis, formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia AML. It is a firstinclass anticancer quinolone derivative that has not been used previously for the treatment...


Tuesday 14th August 2018

Biogen Inc BIIB Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryBiogen Inc Biogen is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company's marketed products include Avonex interferon beta1a, Tysabri natalizumab, Tecfidera dimethyl fumarate, Zinbryta daclizumab, Fampyra prolongedrelease fampridine tablets and Plegridy peginterferon beta1a fo...

Global Bioactive Ingredients Market Growth, Trend and Forecast 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The market was valued is expected to reach over USD 43.25 million by 2023, projecting a healthy CAGR of 6.3% over the forecast period, 20182023. The market has growing extensively due to the increasing global consumption of dietary supplements. Bioactive ingredients are necessary constituents found in most dietary supplements which help in improving the health of consumers. Market DynamicsBioactiv...


STAT Plus: Pharmalittle: U.K. watchdog calls Biogen rare disease drug too pricey; Novartis hires a new ethics officer

The U.K.'s cost-effectiveness agency is not recommending use of the Spinraza treatment sold by Biogen, even after the company offered a discount.

NICE in talks with Biogen after rejecting SMA drug

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in further discussions with the manufacturer to strike a spec...

Draft guidelines reject NHS funding for Biogen’s Spinraza

The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.

Shock as NICE turns down Biogen’s SMA therapy

UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear

Biogen's Spinraza gets an early no-go from NICE

While noting Spinraza's efficacy in the clinic, the U.K. agency concluded it wasn't a cost-effective use of National Health Service resources. 

NICE rejects Biogen's spinal muscular dystrophy drug Spinraza after long delay

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available treatment for the condition. The news is the latest in a series of roadblocks for the drug. Following its approval last year, review of Spinraza was delayed by the institute until January this year because of contention over how to how to handle its ...

Monday 13th August 2018

Global Food Starch Market Growth, Trend and Forecast 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The global starch market is poised to register a CAGR of 5.85%.The market is competitive and driven by an increase in the trend of health and wellness and growing consumer demand for all natural ingredients. Cereals, particularly breads and breakfast cereals, and potatoes make the major contribution to starch intakes in the western diets. Starch intakes are considerably higher in countries depende...

Biogen's pricey muscle drug Spinraza too costly for Britain

Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Samsung Bioepis and Takeda begin first trial from R&D tie-up

Korea’s Samsung Bioepis has begun clinical development of its first ever novel biologic – a protein intended to treat severe acute pancreatitis. A joint venture between Samsung and Biogen, Samsung Bioepis has made its name producing biosimilars in...

Has Amyloid-Based Research Turned The Corner?

Biogen’s recently reported positive Phase 2 trial results for BAN2401 rekindle hopes for the amyloid hypothesis and also more widespread use of amyloid imaging radiopharmaceuticals.

Sunday 12th August 2018

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

SB26, also known as TAK-671, is intended to treat severe acute pancreatitis SB26 is the first therapeutic candidate in the risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda to co-develop multiple novel biologic therapies. Samsung Bioepis Co., Ltd. today announced it will soon begin a ...

Global Alcoholic Drinks Packaging Market Segmented By Material Plastic, Paper, Metal, Glass, Products Type Bottles, Metal Cans, Cartons, Pouches, Products Beer, Spirits, Wine, Ready to Drink and Region Growth, Trends and Forecasts 2018 2023 [Report Upd

The global alcoholic drinks packaging market was valued at USD 27.06 billion in 2017 and is expected to reach a market value of USD 36.38 billion by 2023, registering a CAGR of 5.06% during 2018 2023. Alcoholic drinks consumption is expected to increase in the forecast period, directly influencing the alcoholic drinks packaging market. The type of products considered under the scope of study are ...

Tuesday 7th August 2018

Sunesis Pharmaceuticals Inc SNSS Financial and Strategic SWOT Analysis Review [Report Updated: 19042018] Prices from USD $125

Sunesis Pharmaceuticals Inc SNSS Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that a...

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

Encouraging results of recent clinical trials in Alzheimer's disease indicate importance of selectively targeting toxic amyloid-beta oligomers TORONTO and CAMBRIDGE, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers i...

Biogen Hits A Potential Home Run

Monday 6th August 2018

BioMotiv LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryBioMotiv LLC BioMotiv is a development company specializes in the licensing and development of therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. The company in association with The Harrington Project for Discovery Development accelerates discoveries from research institutions into therapeutics for patients. It provides operating platfo...

North America Spice and Herb Extracts Market Segmented by Type, Application, and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $3850

North America, the market for spice and herb extracts is expected to grow at a CAGR of 7.2% from 2018 to 2023. The market has a good trade potential, especially for smallscale farmers in regions like the US and the Mexico, where a significant local demand exists for spices and herb extracts. A large proportion of extracts traded in both, local and export markets is produced by smallscale farmers a...

Mannatech Reports Second Quarter 2018 Financial Results

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2018. Second Quarter Results Second quarter net

AVEO Pharmaceuticals Inc AVEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryAVEO Pharmaceuticals Inc AVEO is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. The company develops products for oncology and other areas of unmet medical need. It proprietary platform has delivered insights into cancer and related diseases. AVEO develops its lead candidate tivozanib in N...

Sunday 5th August 2018

Biogen Inc BIIB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryBiogen Inc Biogen is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company's marketed products include Avonex interferon beta1a, Tysabri natalizumab, Tecfidera dimethyl fumarate, Zinbryta daclizumab, Fampyra prolongedrelease fampridine tablets and Plegridy peginterferon beta1a fo...

A Roundup of Major Q2 Reports: Biogen, AstraZeneca, Pfizer and More

The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.

Alnylam Pharmaceuticals Inc ALNY Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryAlnylam Pharmaceuticals Inc, Alnylam is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference RNAi. The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for adv...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks